Core Viewpoint - The announcement details the public disclosure and verification of the incentive plan for restricted stock for the year 2025 by Hunan Jinbo Carbon Co., Ltd, ensuring compliance with relevant regulations and confirming the eligibility of the incentive recipients [1][2][3] Group 1: Incentive Plan Overview - The board of directors approved the 2025 restricted stock incentive plan and its management measures during a meeting on July 28, 2025 [1] - The incentive plan's recipient list was publicly disclosed on July 29, 2025, on the Shanghai Stock Exchange website [1][2] - The public disclosure period allowed for feedback from stakeholders regarding the incentive recipients [1] Group 2: Verification Process - The remuneration and assessment committee did not receive any objections regarding the proposed incentive recipients during the public disclosure period [2] - The committee verified the eligibility of the proposed recipients based on their identification, employment contracts, and positions within the company [2][3] Group 3: Eligibility Criteria - The incentive recipients include directors, senior management, core technical personnel, and other individuals deemed necessary for motivation by the board [3] - Exclusions from the incentive plan include independent directors, supervisors, foreign personnel, and shareholders or actual controllers holding more than 5% of the company's shares [3]

Core Viewpoint - The board of directors' remuneration and assessment committee of Tonghua Grape Wine Co., Ltd. has reviewed and approved the draft of the 2025 Restricted Stock Incentive Plan, confirming that it complies with relevant laws and regulations, and does not harm the interests of the company and its shareholders [2][3][4]. Summary by Relevant Sections - The incentive plan is in accordance with the Company Law, Securities Law, and the Management Measures for Equity Incentives of Listed Companies, ensuring that the granting and lifting of restrictions on the stock awards do not violate any legal provisions [3][4]. - The plan specifies that certain conditions must be met for the implementation of the equity incentive plan, including the absence of negative audit opinions on financial reports and compliance with profit distribution regulations [3]. - The eligible recipients of the incentive plan do not include independent directors or shareholders holding more than 5% of the company's shares, ensuring that the plan adheres to the stipulated conditions for incentive recipients [3][4]. - The plan aims to align the interests of employees and shareholders, enhancing employee motivation and creativity, which is expected to improve the company's operational efficiency and long-term sustainable development [4].

Core Points - The company held its ninth board meeting, which was legally valid with all seven directors present, and the meeting was chaired by the chairwoman Wu Yuhua [1] - The board approved the 2025 Restricted Stock Incentive Plan draft, aiming to align the compensation of incentive targets with company performance and strategic goals [2][3] - The plan is designed to enhance the motivation of management and employees, ensuring a focus on the long-term development of the company while safeguarding shareholder interests [1][2] Summary by Sections Board Meeting - The ninth board meeting of the company was conducted via communication, with all seven directors present, confirming its legality and validity [1] - The board unanimously approved the resolution regarding the 2025 Restricted Stock Incentive Plan draft [2] Incentive Plan - The 2025 Restricted Stock Incentive Plan aims to create a balanced value distribution system and motivate key employees to work diligently towards achieving the company's strategic and operational goals [2][4] - The plan will be submitted for approval at the upcoming shareholders' meeting [2][3] Authorization Matters - The board proposed several authorizations for the implementation of the 2025 Restricted Stock Incentive Plan, including determining the grant date and adjusting stock quantities in case of capital changes [4][5] - The board will also manage the granting of restricted stocks and the review of conditions for lifting restrictions on incentive targets [4][5]

Core Viewpoint - Dongguan Kaige Precision Machinery Co., Ltd. is implementing a 2025 restricted stock incentive plan to enhance the motivation and creativity of senior management and core technical personnel, thereby improving the company's competitiveness and aligning the interests of shareholders, the company, and the core team [21][26]. Group 1: Company Overview - Dongguan Kaige Precision Machinery Co., Ltd. was established on May 8, 2005, and its stock has been listed on the Shenzhen Stock Exchange since August 16, 2022, with the stock code 301338 [5][6]. Group 2: Incentive Plan Details - The incentive plan involves granting 586,500 restricted stocks, accounting for approximately 0.55% of the company's total share capital of 10,640,000 shares [12]. - The grant price for the restricted stocks is set at 33.19 RMB per share, which is above the higher of the stock's face value or 50% of the average trading price over the previous 120 trading days [15][16]. - The plan's effective period is from the grant date until all granted stocks are vested or become invalid, with a maximum duration of 60 months [13][14]. Group 3: Eligibility and Compliance - The incentive plan targets 69 individuals, including senior management and core technical personnel, representing 6.07% of the total workforce of 1,137 employees [10][24]. - The plan complies with relevant laws and regulations, ensuring that no individuals with disqualifying conditions are included as incentive recipients [10][25]. Group 4: Performance Assessment - The performance assessment for the incentive plan includes company-level targets, with specific net profit thresholds set for the first and second vesting periods [18][19]. - If the company fails to meet the performance targets, the corresponding restricted stocks will not vest and will be rendered invalid [19][20]. Group 5: Legal and Procedural Compliance - The company has fulfilled necessary legal procedures and obtained required approvals for the implementation of the incentive plan, which will be subject to further shareholder approval [22][24]. - The plan has been disclosed in accordance with regulatory requirements, ensuring transparency and compliance with the management measures [25].

Core Viewpoint - The company has made significant adjustments to its 2024 restricted stock incentive plan, including changes to the grant price and the cancellation of unvested shares for certain employees [1][4][5]. Group 1: Adjustments to Incentive Plan - The board approved an adjustment to the grant price of the 2024 restricted stock incentive plan to approximately 10.67 yuan per share, after accounting for cash dividends [2][6]. - The cash dividend per share for the 2024 interim distribution is adjusted to 0.06921 yuan, and for the annual distribution, it is adjusted to 0.13843 yuan [2]. Group 2: Cancellation of Unvested Shares - A total of 248,175 shares of restricted stock will be canceled due to 27 employees no longer qualifying as incentive recipients and 12 employees not meeting performance standards [4]. - The board's decision to cancel these shares was unanimously approved, with no votes against or abstentions [4]. Group 3: Vesting Conditions - The first vesting period for the incentive plan is set from August 21, 2024, to August 21, 2025, with a total of 1,024,850 shares eligible for vesting [5][6]. - The board has authorized the processing of vesting for 255 qualifying incentive recipients [6].

Core Viewpoint - The legal opinion issued by Guangdong Xinda Law Firm confirms that Shenzhen Xinlong Health Industry Development Co., Ltd. has obtained the necessary approvals for the repurchase and cancellation of certain restricted stocks under its 2023 incentive plan, pending final approval from the shareholders' meeting [1][9]. Group 1: Approval and Authorization - On June 15, 2023, the company held its first extraordinary general meeting of shareholders, which approved the 2023 restricted stock incentive plan and authorized the board of directors to implement the plan [2][3]. - The board is authorized to handle various matters related to the incentive plan, including adjustments to the number and price of restricted stocks in case of stock splits or dividends [3][4]. Group 2: Specifics of the Repurchase - The company plans to repurchase and cancel a total of 1,818,050 shares of restricted stock, which includes 75,000 shares from two departing incentive recipients and 1,743,050 shares that did not meet the release conditions [5][6]. - The repurchase price for the restricted stocks is set at 3.49 yuan per share, adjusted from the previous price of 3.52 yuan [4][5]. Group 3: Performance Targets and Conditions - The incentive plan stipulates that the release of restricted stocks is contingent upon meeting specific performance targets, including a revenue growth rate of no less than 5% for 2024 and 10% for 2025, based on 2022 revenue [7][8]. - The actual performance for the first release period did not meet the targets, leading to the cancellation of the corresponding restricted stocks [9]. Group 4: Legal Compliance - The legal opinion asserts that the repurchase and cancellation of restricted stocks comply with the Company Law, Securities Law, and relevant regulations, but still requires approval from the shareholders' meeting [9][10].

中国上海石门一路 288 号 兴业太古汇香港兴业中心一座 26 层 邮编：200041 电话：（86-21）5298 5488 传真：（86-21）5298 5492 君合律师事务所上海分所 关于益方生物科技（上海）股份有限公司 成就的法律意见书 益方生物科技（上海）股份有限公司： 君合律师事务所上海分所（以下简称"本所"）接受益方生物科技（上海） 股份有限公司（以下简称"公司"或"益方生物"）的委托，担任益方生物 2022 年限制性股票激励计划（以下简称"本次激励计划"）的专项法律顾问，根据《中 华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》 （以下简称"《证券法》"）、《上市公司股权激励管理办法》（以下简称"《管 理办法》"）、《上海证券交易所科创板股票上市规则》（以下简称"《上市规 则》"）、《科创板上市公司自律监管指南第 4 号——股权激励信息披露》（以 下简称"《自律监管指南》"）以及中华人民共和国（包括香港特别行政区、澳 门特别行政区和台湾地区，仅为出具本法律意见书之目的，特指中华人民共和国 大陆地区，以下简称"中国"）其他相关法律、法规及规范性文件的有关规定， 就本次激 ...

证券代码：688382 证券简称：益方生物 公告编号：2025-030 益方生物科技（上海）股份有限公司 关于 2022 年限制性股票激励计划预留授予部分第二 个归属期符合归属条件的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ? 限制性股票拟归属数量：2.0647 万股 ? 归属股票来源：向激励对象定向发行的益方生物科技（上海）股份有 限公司（以下简称"公司"）人民币 A 股普通股股票 一、本次股权激励计划批准及实施情况 （一）本次股权激励计划方案及履行的程序 （1）激励方式：第二类限制性股票 （2）授予数量：553.4115 万股，其中首次授予 461.1762 万股，预留授予 （3）授予价格：4.35 元/股 （4）激励人数：首次授予 71 人，预留授予合计 30 人 （5）本次激励计划首次授予的限制性股票的归属期限和归属安排具体如下： 归属期 归属安排 归属比例 自首次授予部分限制性股票授予日起 12 个月后的 第一个归属期 首个交易日起至首次授予部分限制性股票授予日起 40% 自首次授予部 ...

Core Viewpoint - Shanghai Huaneng Technology Co., Ltd. is repurchasing and canceling a total of 3,498,600 restricted stocks due to the retirement and job changes of certain employees, as well as unmet performance targets for the third release period [2][4]. Group 1: Reasons and Quantity of Repurchase - The company will repurchase 261,800 restricted stocks from 10 employees who have retired or changed jobs [2]. - Additionally, 3,236,800 restricted stocks will be repurchased from 146 employees due to failure to meet performance targets, with a compound annual growth rate of net profit at 0.01%, below the target of 10% [2]. Group 2: Repurchase Price and Adjustments - The adjusted repurchase price for the restricted stocks is calculated to be 2.34921 yuan per share after accounting for multiple cash dividends distributed from 2021 to 2025 [3]. - For the 10 employees whose stocks are being repurchased due to retirement or job changes, the repurchase price will be 2.34921 yuan per share plus the interest from bank deposits [3]. - For the stocks repurchased due to unmet performance targets, the repurchase price will be the lower of the grant price or the market price at the time of repurchase, set at 2.34921 yuan per share [3]. Group 3: Independent Financial Advisor Opinion - The independent financial advisor confirmed that the repurchase and cancellation of restricted stocks, along with the adjustment of repurchase prices, complied with relevant laws and regulations, and did not harm the interests of the company or its shareholders [4].

Meeting Overview - The board meeting of Fujian Haitong Development Co., Ltd. was held on August 20, 2025, with all 7 directors present, ensuring compliance with legal and regulatory requirements [1]. Resolutions Passed Stock Repurchase and Cancellation - The board approved the repurchase and cancellation of a total of 302,600 restricted stocks and 164,000 stock options due to the departure of certain incentive targets and performance issues [1][2]. Stock Option and Restricted Stock Incentive Plan - The board confirmed that the conditions for the first exercise period of the 2024 stock option and restricted stock incentive plan have been met, allowing 13 eligible individuals to exercise a total of 345,000 stock options [2][3]. Release of Restricted Stocks - The board acknowledged that the conditions for the second release period of the 2023 restricted stock incentive plan have been fulfilled, allowing 38 individuals to apply for the release of 1,336,440 restricted stocks, which represents 0.14% of the company's total share capital [3][4]. Quality Improvement Action Plan - The board reviewed and approved the evaluation report of the "Quality Improvement and Return to Shareholders" special action plan for the first half of 2025, which aligns with national economic directives and aims to enhance the company's development and investment value [4][5]. Organizational Structure Adjustment - The board approved adjustments to the company's organizational structure to improve operational efficiency and governance, authorizing management to implement these changes [5].